Umbralisib plus ublituximab benefits patients with CLL and Bruton TKI risk factors

umbralisib plus ublituximab benefits patients with cll and bruton tki risk factors

Sumary of Umbralisib plus ublituximab benefits patients with CLL and Bruton TKI risk factors:

  • Sumary of Umbralisib plus ublituximab benefits patients with CLL and Bruton TKI risk factors: Back to Healio The combination of umbralisib and ublituximab demonstrated superior PFS and overall response rates compared with chemoimmunotherapy among patients with chronic lymphocytic leukemia and Bruton tyrosine kinase inhibitor risk factors.
  • Other conditions, such as joint pain and hypertension, can affect their ability to remain on long-term continuous BTK inhibitor therapy.

Want to know more click here go to sourc

From -

Close

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close